ReviewCancer communications (London, England)2021
Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.
Review in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial.Cancer communications (London, England) · 2023Trial
- Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
- Clinical application of liquid biopsy in the diagnosis and treatment of lung cancer: taking ctDNA for example-a narrative review.Journal of thoracic disease · 2026Review
- Performance of Urine Fluorescence In Situ Hybridization for Diagnosis of Upper Tract Urothelial Carcinoma: A Comprehensive Review.International journal of molecular sciences · 2026Review
- DCUN1D5 is a novel potential biomarker for predicting the prognosis of bladder cancer.Discover oncology · 2025Article
- Translational Insights into NK Immunophenotyping: Comparative Surface Marker Analysis and Circulating Immune Cell Profiling in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Liquid Biopsy: Current advancements in clinical practice for bladder cancer.The journal of liquid biopsy · 2025Review
- Dual Biomarker Strategies for Liquid Biopsy: Integrating Circulating Tumor Cells and Circulating Tumor DNA for Enhanced Tumor Monitoring.Biosensors · 2025Review
- Article
- Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions.Biomolecules · 2024Review
- Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.International journal of molecular sciences · 2024Review
- Exosomal Proteomics: Unveiling Novel Insights into Lung Cancer.Aging and disease · 2024Review
- Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.Cancer science · 2024Review
- New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.Cancers · 2024Review
- Phenotyping neuroblastoma cells through intelligent scrutiny of stain-free biomarkers in holographic flow cytometry.APL bioengineering · 2023Article
- Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.Cancer cytopathology · 2023Article
- Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.Cellular & molecular biology letters · 2023Review
- Approved Nanomedicine against Diseases.Pharmaceutics · 2023Review
- Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.Frontiers in immunology · 2023Article
- Usefulness of the Urine Methylation Test (Bladder EpiCheckJournal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is a heterogeneous disease that characterized by genomic instability and a high mutation rate. Heterogeneity in tumor may partially explain the diversity of responses to targeted therapies and the various clinical outcomes. A combination of cytology and cystoscopy is the standard methodology for BC diagnosis, prognosis, and disease surveillance. However, genomics analyses of single tumor-biopsy specimens may underestimate the mutational burden of heterogeneous tumors. Liquid biopsy, as a promising technology, enables analysis of tumor components in the bodily fluids, such as blood and urine, at multiple time points and provides a minimally invasive approach that can track the evolutionary dynamics and monitor tumor heterogeneity. In this review, we describe the multiple faces of BC heterogeneity at the genomic and transcriptional levels and how they affect clinical care and outcomes. We also summarize the outcomes of liquid biopsy in BC, which plays a potential role in revealing tumor heterogeneity. Finally, we discuss the challenges that must be addressed before liquid biopsy can be widely used in clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.